Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
暂无分享,去创建一个
Y. Kagami | M. Ogura | K. Tobinai | D. Maruyama | K. Itoh | K. Ando | H. Taji | Y. Morishima | Takashi Watanabe | T. Hotta | H. Minami | M. Nakata | Y. Ogawa | T. Tsuchiya | Y. Kobayashi
[1] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[2] R. Millikan,et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[4] G. Morgan,et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.
[5] P. Elliott,et al. Proteasome inhibition measurements: clinical application. , 2000, Clinical chemistry.
[6] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[7] Oken. Management of Myeloma: Current and Future Approaches. , 1998, Cancer control : journal of the Moffitt Cancer Center.
[8] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[9] M. Oken. Standard treatment of multiple myeloma. , 1994, Mayo Clinic proceedings.
[10] A. Paccagnella,et al. Second and third responses to the same induction regimen in relapsing patients with multiple myeloma , 1991, Cancer.
[11] A. Buzaid,et al. Management of refractory myeloma: a review. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] B. Barlogie,et al. High-dose glucocorticoid treatment of resistant myeloma. , 1986, Annals of internal medicine.
[13] B. Barlogie,et al. Effective treatment of advanced multiple myeloma refractory to alkylating agents. , 1984, The New England journal of medicine.